PROs in Spa and PSA: Dr. Rachel Tate ( @uptoTate) https://t.co/sUXTXDXrFh

• https://bit.ly/3wSTLSo

Patients selected to maximise response & minimise adverse events in RA & PsA trials. What implications does this have when we interpret the data & try to apply in clinic? #EULAR2021 https://t.co/CocKlvjme4

Placebo response in PsA trials have more than doubled in last decade. Due to patient characteristics, patient expectations? Makes it very difficult to compare between trials #EULAR2021 https://t.co/XQk4hqrYN8

ERA & JPsA children & adolescents tx'ed w/ SEC, JUNIPERA 104wk data: longer time to flare vs PBO. NRI analysis: 87.2%, 83.7%, 67.4%, 38.4% and 24.4% achieved JIA ACR 30/50/70/90/100, respectively. No new safety signals. #EULAR2021 @RheumNow Abstract #LB004 https://t.co/reWawBWfqh https://t.co/9gzKKU1xrm

• http://ow.ly/TMbx50F1XrE

Moysidou et al reviewed pubmed registries/longitudinal cohort studies in PsA. 27 registries, totaling 30 countries (67% European, 26% N. American) Africa not represented. This is a call to arms for global PsA pts! #EULAR2021 @RheumNow Poster #POS1078 https://t.co/rsQYR6NFNT https://t.co/MU3FVXuRxS

• http://ow.ly/gkVw50F1qW0

We are truly blessed to live in an era when response to RA treatment is the norm. (our forefathers looking on jealously from their gold and pencillinamine towers!) real-world data from BIOBADASER registry OP0123 #EULAR2021 @RheumNow https://t.co/RuQkK1ZXZv

RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, Janssen. All content chosen by RheumNow & its Faculty.

Patient profiles have changed in clinical trials of PsA #EULAR2021 https://t.co/6l2RfOPkSq